Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05735730 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Can the Risk for AMD be Modulated?

Study acronym: AMD_LifeGene
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Jun 6, 2025 to Jan 12, 2028v7
  2. Study completion date: Feb 6, 2025 to Jun 6, 2025v6
  3. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 2024 to Feb 6, 2025
    • Study completion date: May 2025 to Feb 6, 2025
    • Site details revised
    v5
  4. Trial status: Active, Not Recruiting to Recruitingv4 Show 6 more changesShow less
    • Start date: Apr 28, 2023 to Jun 26, 2023
    • Primary completion date: Sep 2024 to Dec 2024
    • Study completion date: Jan 2025 to May 2025
    • Eligibility criteria revised
    • Study description expanded, about 8 words
    • Site details revised
  5. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Apr 2023 to Apr 28, 2023
    • Site contact updated
    v3
  6. Secondary endpoints: 3 to 4
    • Study description expanded, about 207 words
    • Eligibility criteria shortened, about 3 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this Cross-sectional, interventional study is to learn about whether different risk factors, as Mediterranean diet, lifestyle and concomitant medication can modulate the risk imprinted by genetics in Age-related macular degeneration (AMD). The main question it aims to answer is: How the genetic risk interacts with environmental and lifestyle factors, especially Mediterranean diet and chronic medication, in order to assess how this interplay protects or presents higher risk for the establishment or the progression of AMD. Participants: Vital Signs will be measured; Medical History, Demographics, Nutritional/lifestyle habits and Family History of AMD will be recorded; Ophthalmological Examination will be performed Genetic analysis will be performed.
Trial Details
NCT Number NCT05735730
Lead Sponsor Association for Innovation and Biomedical Research on Light and Image
Conditions
(from sponsor)		 Age-Related Macular Degeneration (ARMD)
Related terms Macular Degeneration
Enrollment 1,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov